These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis. Modena P; Buttarelli FR; Miceli R; Piccinin E; Baldi C; Antonelli M; Morra I; Lauriola L; Di Rocco C; Garrè ML; Sardi I; Genitori L; Maestro R; Gandola L; Facchinetti F; Collini P; Sozzi G; Giangaspero F; Massimino M Neuro Oncol; 2012 Nov; 14(11):1346-56. PubMed ID: 23076205 [TBL] [Abstract][Full Text] [Related]
3. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. Tabori U; Ma J; Carter M; Zielenska M; Rutka J; Bouffet E; Bartels U; Malkin D; Hawkins C J Clin Oncol; 2006 Apr; 24(10):1522-8. PubMed ID: 16575002 [TBL] [Abstract][Full Text] [Related]
4. Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients. Chen C; Chen L; Yao Y; Qin Z; Chen H J Neurooncol; 2016 Mar; 127(1):43-52. PubMed ID: 26615563 [TBL] [Abstract][Full Text] [Related]
5. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study. Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788 [TBL] [Abstract][Full Text] [Related]
6. Nestin expression identifies ependymoma patients with poor outcome. Milde T; Hielscher T; Witt H; Kool M; Mack SC; Deubzer HE; Oehme I; Lodrini M; Benner A; Taylor MD; von Deimling A; Kulozik AE; Pfister SM; Witt O; Korshunov A Brain Pathol; 2012 Nov; 22(6):848-60. PubMed ID: 22568867 [TBL] [Abstract][Full Text] [Related]
7. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Wolfsberger S; Fischer I; Höftberger R; Birner P; Slavc I; Dieckmann K; Czech T; Budka H; Hainfellner J Am J Surg Pathol; 2004 Jul; 28(7):914-20. PubMed ID: 15223962 [TBL] [Abstract][Full Text] [Related]
8. Analysis of the prognostic significance of selected morphological and immunohistochemical markers in ependymomas, with literature review. Zawrocki A; Iżycka-Świeszewska E; Papierz W; Liberski PP; Zakrzewski K; Biernat W Folia Neuropathol; 2011; 49(2):94-102. PubMed ID: 21845537 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas. Dorris K; Sobo M; Onar-Thomas A; Panditharatna E; Stevenson CB; Gardner SL; Dewire MD; Pierson CR; Olshefski R; Rempel SA; Goldman S; Miles L; Fouladi M; Drissi R J Neurooncol; 2014 Mar; 117(1):67-76. PubMed ID: 24477622 [TBL] [Abstract][Full Text] [Related]
10. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma. Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862 [TBL] [Abstract][Full Text] [Related]
11. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. Barszczyk M; Buczkowicz P; Castelo-Branco P; Mack SC; Ramaswamy V; Mangerel J; Agnihotri S; Remke M; Golbourn B; Pajovic S; Elizabeth C; Yu M; Luu B; Morrison A; Adamski J; Nethery-Brokx K; Li XN; Van Meter T; Dirks PB; Rutka JT; Taylor MD; Tabori U; Hawkins C Acta Neuropathol; 2014 Dec; 128(6):863-77. PubMed ID: 25120190 [TBL] [Abstract][Full Text] [Related]
12. Telomerase inhibition as a novel therapy for pediatric ependymoma. Wong VC; Morrison A; Tabori U; Hawkins CE Brain Pathol; 2010 Jul; 20(4):780-6. PubMed ID: 20184588 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical markers for prognosis of ependymal neoplasms. Korshunov A; Golanov A; Timirgaz V J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. Korshunov A; Golanov A; Timirgaz V J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185 [TBL] [Abstract][Full Text] [Related]
15. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Preusser M; Wolfsberger S; Czech T; Slavc I; Budka H; Hainfellner JA Am J Clin Pathol; 2005 Oct; 124(4):543-9. PubMed ID: 16146813 [TBL] [Abstract][Full Text] [Related]
16. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821 [TBL] [Abstract][Full Text] [Related]
17. Prognostic marker analysis in pediatric intracranial ependymomas. McLendon RE; Lipp E; Satterfield D; Ehinger M; Austin A; Fleming D; Perkinson K; Lefaivre M; Zagzag D; Wiener B; Gururangan S; Fuchs H; Friedman HS; Herndon JE; Healy P J Neurooncol; 2015 Apr; 122(2):255-61. PubMed ID: 25563815 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China. Xi S; Sai K; Hu W; Wang F; Chen Y; Wang J; Zeng J; Chen Z BMC Cancer; 2019 Jul; 19(1):717. PubMed ID: 31324163 [TBL] [Abstract][Full Text] [Related]
19. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018 [TBL] [Abstract][Full Text] [Related]
20. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Kilday JP; Mitra B; Domerg C; Ward J; Andreiuolo F; Osteso-Ibanez T; Mauguen A; Varlet P; Le Deley MC; Lowe J; Ellison DW; Gilbertson RJ; Coyle B; Grill J; Grundy RG Clin Cancer Res; 2012 Apr; 18(7):2001-11. PubMed ID: 22338015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]